J&J Skips GLP-1, Doubles Down on Oncology Target

What happened

Johnson & Johnson CEO Joaquin Duato confirmed the company will not enter the GLP-1 obesity drug race, instead aiming to become the number one oncology company by 2030. This strategic decision aligns with J&J's ongoing pivot toward high-growth oncology and immunology franchises, which already generated ~$25.4 billion in 2025. However, the GLP-1 skip removes a potential future revenue stream, putting even more pressure on existing oncology assets like Darzalex and Carvykti to offset the Stelara patent cliff and looming Darzalex loss of exclusivity. The move is consistent with J&J's recent capital allocation but does not address the fundamental uncertainties around drug pricing, talc litigation, and rising net debt. Investors should view this as a reinforcement of the current strategy, not a new catalyst.

Implication

J&J's oncology-centric strategy still hinges on flawless execution to offset multiple LOEs, especially Stelara and eventually Darzalex. The GLP-1 skip confirms management's discipline but also removes a potential growth lever; if oncology disappoints, there is no metabolic fallback. The stock's ~47% rally over the past year already reflects this pivot, leaving limited upside from current levels given the unresolved talc and pricing overhangs.

Thesis delta

This news reinforces J&J's existing strategic direction and does not alter our fundamental thesis. The key risk remains identical: can Innovative Medicine ex-Stelara sustain 10%+ growth while talc and IRA headwinds remain unresolved? Our base case of ~$215 fair value and WAIT rating stands. The GLP-1 skip eliminates a low-probability upside scenario but doesn't change the bear case.